Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck MRK announced that the FDA has accepted ... clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease entering their first RSV season.

Just two years ago, there were no vaccines approved to prevent respiratory syncytial virus ... This week, The FDA accepted Merck & Co.’s biologics license application for the monoclonal ...